Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Director | December 08, 2020 | December 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date December 08, 2020 · Filed December 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2030-12-08 | Direct | 23,000 |
Reported balance
After 2020-12-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-08 · Grant · Acquired 23,000 · Balance 23,000 F1: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABAXIS INC
Report date July 31, 2018 · Filed August 02, 2018
Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-07-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-07-31 · Gift · Disposed 300 · Balance 57,100 Row 2 · 2018-07-31 · Disposition to issuer · Disposed 57,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated May 15, 2018, by and among Abaxis, Inc., a California corporation (the "Issuer"), Zoetis Inc., a Delaware corporation ("Parent"), and Zeus Merger Sub, Inc., a California corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), on July 31, 2018, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, these shares were cancelled and converted into the right to receive $83.00 in cash, without interest, per share, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-07-31 · Disposition to issuer · Disposed 5,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of these unvested restricted stock units vested automatically in accordance with their existing terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. Each of these vested restricted stock units converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. F3: Not applicable. |
| Common StockSEC Table I · non-derivative | IndirectHeld by Spouse | 300 |
Reported balance
Holding disclosure · report date 2018-07-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 300 |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated May 15, 2018, by and among Abaxis, Inc., a California corporation (the "Issuer"), Zoetis Inc., a Delaware corporation ("Parent"), and Zeus Merger Sub, Inc., a California corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), on July 31, 2018, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, these shares were cancelled and converted into the right to receive $83.00 in cash, without interest, per share, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration").
F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of these unvested restricted stock units vested automatically in accordance with their existing terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. Each of these vested restricted stock units converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards.
F3: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 08, 2020 Filed Dec 9, 2020 21:06 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001104659-20-133631 · tm2038059-3_4seq1.xml · derivative · entry 1 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| May 22, 2019 Filed May 25, 2019 01:30 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 27,383 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001144204-19-028253 · tv522358_4.xml · derivative · entry 1 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,383 Underlying: Common Stock · 27,383 shares Expires 2029-05-22 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each annual anniversary of the date of grant. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 19:55 UTC | ABAXIS INC ABAX · Entity 164580 | Disposition to issuerRestricted Stock Units · Derivative | 5,500 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001140361-18-035272 · doc1.xml · derivative · entry 4 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of these unvested restricted stock units vested automatically in accordance with their existing terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. Each of these vested restricted stock units converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of these unvested restricted stock units vested automatically in accordance with their existing terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. Each of these vested restricted stock units converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. F3 · derivative.expiration_date: Not applicable. F2 · balance_after: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of these unvested restricted stock units vested automatically in accordance with their existing terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. Each of these vested restricted stock units converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 19:55 UTC | ABAXIS INC ABAX · Entity 164580 | Disposition to issuerCommon Stock | 57,100 | $83.00 | $4,739,300.00 |
DisclosureSEC source: 0001140361-18-035272 · doc1.xml · nonDerivative · entry 2 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated May 15, 2018, by and among Abaxis, Inc., a California corporation (the "Issuer"), Zoetis Inc., a Delaware corporation ("Parent"), and Zeus Merger Sub, Inc., a California corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), on July 31, 2018, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, these shares were cancelled and converted into the right to receive $83.00 in cash, without interest, per share, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration"). Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 19:55 UTC | ABAXIS INC ABAX · Entity 164580 | GiftCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-035272 · doc1.xml · nonDerivative · entry 1 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,100 Read SEC document |
| May 01, 2018 Filed May 2, 2018 19:04 UTC | ABAXIS INC ABAX · Entity 164580 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-021353 · doc1.xml · derivative · entry 4 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit represents a contingent right to receive one share of Abaxis common stock. F2 · derivative.exercise_date: Granted under the Abaxis 2014 Equity Incentive Plan. Restricted stock units fully vest 100% after one year. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| May 01, 2018 Filed May 2, 2018 19:04 UTC | ABAXIS INC ABAX · Entity 164580 | Exercise / conversionCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-021353 · doc1.xml · nonDerivative · entry 1 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2018 Filed May 2, 2018 19:04 UTC | ABAXIS INC ABAX · Entity 164580 | GrantRestricted Stock Units · Derivative | 5,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-021353 · doc1.xml · derivative · entry 3 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires not disclosed F1 · security: Each restricted stock unit represents a contingent right to receive one share of Abaxis common stock. F2 · derivative.exercise_date: Granted under the Abaxis 2014 Equity Incentive Plan. Restricted stock units fully vest 100% after one year. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| May 02, 2017 Filed May 3, 2017 21:29 UTC | ABAXIS INC ABAX · Entity 164580 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-018337 · doc1.xml · derivative · entry 4 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit represents a contingent right to receive one share of Abaxis common stock. F2 · derivative.exercise_date: Granted under the Abaxis 2014 Equity Incentive Plan. Restricted stock units fully vest 100% after one year. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| May 02, 2017 Filed May 3, 2017 21:29 UTC | ABAXIS INC ABAX · Entity 164580 | Exercise / conversionCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-018337 · doc1.xml · nonDerivative · entry 1 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2017 Filed May 3, 2017 21:29 UTC | ABAXIS INC ABAX · Entity 164580 | GrantRestricted Stock Units · Derivative | 5,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-018337 · doc1.xml · derivative · entry 3 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires not disclosed F1 · security: Each restricted stock unit represents a contingent right to receive one share of Abaxis common stock. F2 · derivative.exercise_date: Granted under the Abaxis 2014 Equity Incentive Plan. Restricted stock units fully vest 100% after one year. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 100 | $51.15 | $5,114.50 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 13 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,400 Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 200 | $50.73 | $10,146.00 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 12 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 300 | $50.72 | $15,214.50 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 11 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,700 Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 100 | $50.71 | $5,071.00 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 10 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 200 | $50.68 | $10,136.00 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 9 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,100 Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 300 | $50.67 | $15,201.00 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 8 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,300 Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 130 | $50.66 | $6,585.80 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 7 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,600 Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 270 | $50.65 | $13,675.50 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 6 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,730 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 200 | $51.50 | $10,300.00 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 5 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 100 | $51.48 | $5,147.50 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 4 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,200 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 100 | $51.42 | $5,141.50 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 3 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,300 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 778 | $51.40 | $39,989.20 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 2 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,400 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:43 UTC | ABAXIS INC ABAX · Entity 164580 | SaleCommon Stock | 1,222 | $51.35 | $62,749.70 |
DisclosureSEC source: 0001140361-17-004432 · doc1.xml · nonDerivative · entry 1 BASTIANI RICHARD · CIK 0001202053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,178 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.